• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses.

作者信息

Berger Christoph T, Rebholz-Chaves Birke, Recher Mike, Manigold Tobias, Daikeler Thomas

机构信息

Clinical Immunology, Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland

Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.

出版信息

Ann Rheum Dis. 2019 Jul;78(7):1012-1014. doi: 10.1136/annrheumdis-2018-214704. Epub 2019 Jan 22.

DOI:10.1136/annrheumdis-2018-214704
PMID:30670375
Abstract
摘要

相似文献

1
Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses.在接受托珠单抗治疗的大血管血管炎患者中进行连续白细胞介素-6测量可检测感染情况，并可能预测早期复发。
Ann Rheum Dis. 2019 Jul;78(7):1012-1014. doi: 10.1136/annrheumdis-2018-214704. Epub 2019 Jan 22.
2
Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.托珠单抗治疗大血管血管炎（巨细胞动脉炎、Takayasu 动脉炎）和多发性肌炎。
Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9. doi: 10.1002/acr.21750.
3
Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis.白细胞介素-6在风湿性多肌痛和巨细胞动脉炎临床复发中的作用
Ann Rheum Dis. 1996 Jun;55(6):403-4. doi: 10.1136/ard.55.6.403-b.
4
Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis.大血管血管炎的影像学、临床和血清学疾病活动评估的治疗效果。
J Rheumatol. 2020 Jan;47(1):99-107. doi: 10.3899/jrheum.181222. Epub 2019 Mar 15.
5
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.托珠单抗治疗糖皮质激素治疗的活动性多发性肌痛患者的疾病活动度：一项随机临床试验。
JAMA. 2022 Sep 20;328(11):1053-1062. doi: 10.1001/jama.2022.15459.
6
Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.多肌痛和巨细胞动脉炎中的α1-抗糜蛋白酶、C反应蛋白及红细胞沉降率
Br J Rheumatol. 1994 Jun;33(6):550-4. doi: 10.1093/rheumatology/33.6.550.
7
Diagnosing and managing polymyalgia rheumatica and temporal arteritis. Repeated measurements of erythrocyte sedimentation rate are not efficient use of time or resources.诊断和管理风湿性多肌痛和颞动脉炎。重复测量红细胞沉降率并非有效利用时间或资源的方式。
BMJ. 1997 Aug 30;315(7107):550.
8
Polymyalgia rheumatica and giant cell arteritis.风湿性多肌痛和巨细胞动脉炎。
Annu Rev Med. 1978;29:15-22. doi: 10.1146/annurev.me.29.020178.000311.
9
Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛与疾病活动相关的血清标志物。
Rheumatology (Oxford). 2015 Aug;54(8):1397-402. doi: 10.1093/rheumatology/keu526. Epub 2015 Feb 26.
10
[Tocilizumab for treatment of large vessel vasculitis and polymyalgia rheumatica].托珠单抗治疗大动脉血管炎和风湿性多肌痛
Z Rheumatol. 2013 Jun;72(5):486-7. doi: 10.1007/s00393-013-1177-y.

引用本文的文献

1
The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease.巨细胞动脉炎的固有面貌：深入了解细胞和分子固有免疫途径以揭示新的潜在疾病生物标志物。
Front Mol Med. 2022 Aug 4;2:933161. doi: 10.3389/fmmed.2022.933161. eCollection 2022.
2
Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic.在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行期间，从抗B细胞疗法转换后，奥洛珠单抗治疗类风湿性关节炎患者的疗效和安全性的12周开放标签、非干预性研究结果。
Dokl Biochem Biophys. 2024 Oct;518(1):291-299. doi: 10.1134/S1607672924701060. Epub 2024 Jul 1.
3
New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritis.用于巨细胞动脉炎疾病分层和监测的新型血液生物标志物和影像学方法。
RMD Open. 2024 Feb 23;10(1):e003397. doi: 10.1136/rmdopen-2023-003397.
4
Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency.移植后炎症性肠病与供体来源的 TIM-3 缺乏有关。
J Clin Immunol. 2024 Feb 16;44(3):63. doi: 10.1007/s10875-024-01667-z.
5
Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?巨细胞动脉炎和风湿性多肌痛靶向治疗时代的生物标志物：是否有可能替代急性期反应物？
Front Immunol. 2023 Jun 15;14:1202160. doi: 10.3389/fimmu.2023.1202160. eCollection 2023.
6
Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force.评估巨细胞动脉炎的治疗结局和疾病活动变化：一项系统文献回顾，代表巨细胞动脉炎 EULAR-ACR 反应标准工作组为 EULAR-ACR 反应标准的制定提供信息。
RMD Open. 2023 Jun;9(2). doi: 10.1136/rmdopen-2023-003233.
7
Disease stratification in GCA and PMR: state of the art and future perspectives.巨细胞动脉炎和 PMR 中的疾病分层：现状与未来展望。
Nat Rev Rheumatol. 2023 Jul;19(7):446-459. doi: 10.1038/s41584-023-00976-8. Epub 2023 Jun 12.
8
Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial).巨细胞动脉炎患者在接受三天糖皮质激素脉冲治疗后序贯托珠单抗单药治疗的血清蛋白质组学研究（GUSTO 试验）。
Front Immunol. 2023 May 23;14:1165758. doi: 10.3389/fimmu.2023.1165758. eCollection 2023.
9
Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.皮下托珠单抗单一疗法成功治疗巨细胞动脉炎。
Rheumatol Int. 2023 Mar;43(3):545-549. doi: 10.1007/s00296-022-05217-x. Epub 2022 Sep 24.
10
Pathogenic role of monocytes/macrophages in large vessel vasculitis.单核细胞/巨噬细胞在大血管血管炎中的致病作用。
Front Immunol. 2022 Jul 29;13:859502. doi: 10.3389/fimmu.2022.859502. eCollection 2022.